Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.
Blommestein HM, de Groot S, Leeneman B, Uyl-de Groot CA, Haanen JBAG, Wouters MWJM, Aarts MJB, van den Berkmortel FWPJ, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Hospers GAP, Kapiteijn E, van Not OJ, van der Veldt AAM, Suijkerbuijk KPM, Franken MG.
Blommestein HM, et al.
Eur J Cancer. 2024 Oct 16;218:115071. doi: 10.1016/j.ejca.2024.115071. Online ahead of print.
Eur J Cancer. 2024.
PMID: 39914026